Edgewell Personal Care closes the week at $22.83, up nearly 6% on Tuesday alone. Shorts have been stepping back. The Q2 earnings call drops on May 8 — and the setup is more interesting than the stock's quiet reputation suggests.
The short interest story tells you where this move came from. Bears built positions aggressively through April — SI % of free float climbed from around 9% in late March to a peak near 12.1% by late April, a jump of roughly a third in four weeks. Since then, the position has been slowly unwinding. As of May 5, SI sits at 11.96% of free float, down about 1.7% on the week. That retreat is modest — shorts haven't been squeezed out — but the direction of travel has clearly shifted ahead of the print. Days to cover of 7.8 means unwinding any meaningful short would take time, which raises the stakes for Friday's result. The borrow market is relaxed: availability is wide, and cost to borrow has eased around 15% over the past month to roughly 0.42% annualised. No squeeze mechanics here — this is an orderly repositioning ahead of an event.
Options positioning reinforces that the mood is less bearish than it was. The put/call ratio has fallen steadily from 2.15 in late March to 1.65 now — still above 1, meaning more puts than calls in open interest, but the trend is one of progressively lighter downside hedging. The ratio is almost exactly at its 20-day average, with a z-score near zero. That neutrality is the signal: traders who were actively reaching for protection two months ago have largely dialled it back. The 52-week range on PCR runs from 0.36 to 2.62, so current readings are far from either extreme.
The Street's position is cautious but not hostile. The mean analyst price target — which has not been updated since early April and reflects actions from February — sits at $24.17, implying around 6% upside from here. The most recent moves in the analyst community came post-Q1, when both Barclays (to $21) and Wells Fargo (to $22) nudged targets higher while keeping ratings unchanged. Those targets are now modestly below current price, which may prompt fresh revisions after the May 8 call. EV/EBITDA is running at roughly 9x and the trailing PE at 11.5x — both suggesting the stock is valued conservatively relative to consumer staples peers. Against that, the bear case centres on continued North American volume softness across Wet Shave and Feminine Care, plus tariff headwinds that are eating into margins faster than gross margin expansion can offset. The bull case rests on international momentum and a company-guided EBITDA target of $334 million. The EPS surprise factor score at the 96th percentile is a consistent reminder that Edgewell has a history of clearing a low bar.
The single historical earnings reaction in the dataset points to a pattern worth noting. After the February 2026 Q1 report, the stock slipped 1.2% on the day but recovered sharply over the following five days, gaining 6.5% by the end of the week. That day-one stumble-then-recover dynamic has played out before with earnings that initially disappoint on the headline but hold up as investors digest the details.
BlackRock holds 15.3% and Vanguard 11.8%, making the register institutionally tight — there is little retail float here. Brandes Investment Partners sits at 13.1%, a value-oriented owner that built its position aggressively through 2025. That ownership mix tends to absorb volatility rather than amplify it. Norges Bank added 1.24 million shares in 2025, a meaningful commitment for a name this size.
The Q2 call on May 8 is the obvious next read. Watch whether management resets tariff guidance — that was the primary lever bears used to build into April — and whether North American volumes show any sequential improvement. The short base is still near its highest level in six months, so any upside surprise on volumes or maintained EBITDA guidance arrives with meaningful covering pressure still sitting in the wings.
See the live data behind this article on ORTEX.
Open EPC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
